SOHO 2022 Tenth Annual Meeting
J

SOHO 2022: Has R-CHOP Really Been Replaced as Initial Therapy of DLBCL?

By SOHO 2022 Tenth Annual Meeting FEATURING Jonathan Friedberg
By SOHO 2022 Tenth Annual Meeting FEATURING Jonathan Friedberg
979 views
October 14, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
10:04
Tara Graff

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

22:09
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024

New Updates in Frontline DLCBL

Feat. L. Nastoupil
62:02
UChicago Medicine

New Treatment Strategies in DLBCL

Feat. L. Sehn
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

25:44
Tara Graff

DLBCL Updates From iCML 2023

06:09
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Outcomes of Pts With Richter's Transfo…

Feat. A. Kittai
35:28
UNC Lineberger Comprehensive Cancer Center

DLBCL Management: Updates for 2023

Feat. N. Grover
17:11
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Incorporating Novel Agents in Frontline DLBCL

Feat. L. Sehn
16:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

2024 Targeted Therapy Updates for Aggressive B-Cell Lymphomas

Feat. D. Landsburg
26:58
Total Health

Update on Cellular Therapy in Lymphoma

Feat. B. Randolph
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Chronic GVHD: A Case-Based Discussion

Feat. L. Perry
15:31
SOHO 2022 Tenth Annual Meeting

SOHO 2022: What's Next in Aggressive B-Cell Lymphoma?

Feat. L. Sehn
35:24
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

Feat. G. Nowakowski
33:36
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: Cell Therapy

Feat. M. de Lima
13:46
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Smart Stop Trial - Lenalidomide, Tafasitama…

Feat. J. Westin
47:35
University of Colorado Division of Hematology

Overview of DLBCL: Diagnosis to Treatment

Feat. E. Fahey-Harrison
02:53
PrecisCa

The POLARIX Trial: Polatuzumab With R-CHP in DLBCL

Feat. M. Kamdar
33:48
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: B-Cell Lymphoma

Feat. L. Nastoupil
14:28
ASH 2022 Conference Coverage

ASH 2022 CNS Prophylaxis in Aggressive B-Cell Lymphoma

Feat. K. Cwynarski